FDA Approves Ready-To-Use Antibacterial Injection
The FDA has approved a ready-to-use clindamycin injection in saline in 3 formulations (300mg/50mL, 600mg/50mL, 900mg/50mL).
Clindamycin, a lincosamide antibacterial, is indicated for the treatment of infectious due to susceptible strains of Streptococci, Pneumococci and Staphylococci, lower respiratory tract infections, skin and skin structure infections, gynecological infections, intra-abdominal infections, septicema, bone and join infections, and serious infections caused by susceptible anaerobic bacteria.
Common Antibiotic Not Linked to Serious Arrhythmia
Single Antibiotic Noninferior to Combo Drug for Pneumonia
The new approval provides clinicians with an alternative for the administration of clindamycin in patients for whom the use of dextrose is contraindicated or undesirable.
Clindamycin injection is contraindicated in patients with a history of hypersensitivity to clindamycin or lincomycin, and should be avoided in atopic individuals. The most common adverse reactions include gastrointestinal and hypersensitivity reactions.
Baxter announces U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline [press release]. Deerfield, Illinois. June 7, 2017. http://www.baxter.com/news-media/newsroom/press-releases/2017/06-07-17-clinda-saline-approval-and-launch.page.